{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:14:46Z","timestamp":1793726086064,"version":"4.6.1"},"reference-count":46,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.bulcan.2024.12.004","type":"journal-article","created":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T12:28:58Z","timestamp":1734784138000},"page":"340-347","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Actualit\u00e9s sur la leuc\u00e9mie \u00e0 tricholeucocytes"],"prefix":"10.1016","volume":"112","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6863-9992","authenticated-orcid":false,"given":"Xavier","family":"Troussard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Maitre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urbain","family":"Tauveron-Jalenques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Paillassa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Inchiappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Tomowiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.bulcan.2024.12.004_bib0235","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.bulcan.2024.12.004_bib0240","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bulcan.2024.12.004_bib0245","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1038\/s41375-024-02280-0","article-title":"Hairy cell leukemia variant and WHO classification correspondence Re: 5th\u00a0edition WHO classification haematolymphoid tumors: lymphoid neoplasms","volume":"38","author":"Grever","year":"2024","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.bulcan.2024.12.004_bib0250","doi-asserted-by":"crossref","first-page":"e8869","DOI":"10.1002\/ccr3.8869","article-title":"Non-nodal mantle cell lymphoma mimicking hairy cell leukemia","volume":"12","author":"Nato","year":"2024","journal-title":"Clin Case Rep"},{"issue":"4","key":"10.1016\/j.bulcan.2024.12.004_bib0255","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/ajh.27240","article-title":"Hairy cell leukemia 2024: update on diagnosis, risk-stratification, and treatment-Annual updates in hematological malignancies","volume":"99","author":"Troussard","year":"2024","journal-title":"Am J Hematol"},{"issue":"Suppl. 1","key":"10.1016\/j.bulcan.2024.12.004_bib0260","first-page":"57","article-title":"The immunophenotype of hairy cell leukemia (HCL). Proposal for a scoring system to distinguish HCL from B-cell disorders with hairy or villous lymphocytes","volume":"14","author":"Matutes","year":"1994","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.bulcan.2024.12.004_bib0265","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.3390\/cancers14041050","article-title":"Immunophenotypic analysis of hairy cell leukemia (HCL) and hairy cell leukemia-like (HCL-like) disorders","volume":"14","author":"Maitre","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.bulcan.2024.12.004_bib0270","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1038\/leu.2009.178","article-title":"Defining origins of malignant B cells: a new circulating normal human IgM(+)D(+) B-cell subset lacking CD27\u00a0expression and displaying somatically mutated IGHV genes as a relevant memory population","volume":"23","author":"Weston-Bell","year":"2009","journal-title":"Leukemia"},{"issue":"24","key":"10.1016\/j.bulcan.2024.12.004_bib0275","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1056\/NEJMoa1014209","article-title":"BRAF mutations in hairy-cell leukemia","volume":"364","author":"Tiacci","year":"2011","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.bulcan.2024.12.004_bib0280","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/bjh.12735","article-title":"Alternative BRAF mutations in BRAF V600E-negative hairy cell leukaemias","volume":"165","author":"Tschernitz","year":"2014","journal-title":"Br J Haematol"},{"issue":"17","key":"10.1016\/j.bulcan.2024.12.004_bib0285","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1111\/jcmm.17890","article-title":"Hairy cell leukaemia with unusual BRAF mutations","volume":"27","author":"Maitre","year":"2023","journal-title":"J Cell Mol Med"},{"issue":"9","key":"10.1016\/j.bulcan.2024.12.004_bib0290","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.32604\/or.2024.051218","article-title":"Non-canonical BRAF variants and rearrangements in hairy cell leukemia","volume":"32","author":"Langabeer","year":"2024","journal-title":"Oncol Res"},{"issue":"1","key":"10.1016\/j.bulcan.2024.12.004_bib0295","doi-asserted-by":"crossref","first-page":"12528","DOI":"10.1038\/s41598-022-16556-x","article-title":"Structure-based prediction of BRAF mutation classes using machine-learning approaches","volume":"12","author":"Krebs","year":"2022","journal-title":"Sci Rep"},{"issue":"8","key":"10.1016\/j.bulcan.2024.12.004_bib0300","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.3390\/cancers14081904","article-title":"Deciphering genetic alterations of hairy cell leukemia and hairy cell leukemia-like disorders in 98\u00a0patients","volume":"14","author":"Maitre","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.bulcan.2024.12.004_bib0305","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/s41375-023-01823-1","article-title":"The genomic landscape and clonal evolutionary trajectory of classical hairy cell leukemia","volume":"37","author":"Moreno Rueda","year":"2023","journal-title":"Leukemia"},{"issue":"21","key":"10.1016\/j.bulcan.2024.12.004_bib0310","doi-asserted-by":"crossref","first-page":"4696","DOI":"10.1182\/blood-2009-03-212449","article-title":"Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior","volume":"114","author":"Forconi","year":"2009","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.bulcan.2024.12.004_bib0315","doi-asserted-by":"crossref","first-page":"4687","DOI":"10.1182\/blood-2009-01-201731","article-title":"VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy","volume":"114","author":"Arons","year":"2009","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bulcan.2024.12.004_bib0320","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1182\/bloodadvances.2019000980","article-title":"Primary vitreoretinal lymphomas display a remarkably restricted immunoglobulin gene repertoire","volume":"4","author":"Belhouachi","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.bulcan.2024.12.004_bib0325","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/ng.2828","article-title":"High prevalence of MAP2K1\u00a0mutations in variant and IGHV4-34-expressing hairy-cell leukemias","volume":"46","author":"Waterfall","year":"2014","journal-title":"Nat Genet"},{"issue":"7","key":"10.1016\/j.bulcan.2024.12.004_bib0330","first-page":"e16239","article-title":"A rare case of a patient with Hairy Cell Leukemia developing blastoid marginal zone B-cell lymphoma","volume":"13","author":"Teklie","year":"2021","journal-title":"Cureus"},{"issue":"10","key":"10.1016\/j.bulcan.2024.12.004_bib0335","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/S0046-8177(99)90031-X","article-title":"Splenic marginal zone lymphoma with increased number of blasts: an aggressive variant?","volume":"30","author":"Lloret","year":"1999","journal-title":"Hum Pathol"},{"issue":"3","key":"10.1016\/j.bulcan.2024.12.004_bib0340","doi-asserted-by":"crossref","first-page":"e18060","DOI":"10.1111\/jcmm.18060","article-title":"Untangling hairy cell leukaemia (HCL) variant and other HCL-like disorders: diagnosis and treatment","volume":"28","author":"Troussard","year":"2024","journal-title":"J Cell Mol Med"},{"issue":"4","key":"10.1016\/j.bulcan.2024.12.004_bib0345","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1182\/blood-2007-07-098848","article-title":"Splenic red pulp lymphoma with numerous basophilic villous lymphocytes: a distinct clinicopathologic and molecular entity?","volume":"111","author":"Traverse-Glehen","year":"2008","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bulcan.2024.12.004_bib0350","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1182\/blood-2016-11-751024","article-title":"Splenic diffuse red pulp small B-cell lymphoma displays increased expression of cyclin D3\u00a0and recurrent CCND3\u00a0mutations","volume":"129","author":"Curiel-Olmo","year":"2017","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bulcan.2024.12.004_bib0355","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.3324\/haematol.2016.160192","article-title":"Exome sequencing identifies recurrent BCOR alterations and the absence of KLF2, TNFAIP3\u00a0and MYD88\u00a0mutations in splenic diffuse red pulp small B-cell lymphoma","volume":"102","author":"Jallades","year":"2017","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.bulcan.2024.12.004_bib0360","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.3390\/curroncol28050297","article-title":"New Insights into the biology and diagnosis of splenic marginal zone lymphomas","volume":"28","author":"Donzel","year":"2021","journal-title":"Curr Oncol"},{"issue":"5","key":"10.1016\/j.bulcan.2024.12.004_bib0365","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1182\/blood-2016-01-689422","article-title":"Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia","volume":"129","author":"Grever","year":"2017","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bulcan.2024.12.004_bib0370","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.3390\/cancers16122185","article-title":"Recommendations for the management of patients with hairy-cell leukemia and hairy-cell leukemia-like disorders: a work by French-speaking experts and French Innovative Leukemia Organization (FILO) Group","volume":"16","author":"Paillassa","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"Suppl. 2","key":"10.1016\/j.bulcan.2024.12.004_bib0375","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3109\/10428194.2011.568650","article-title":"Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence","volume":"52","author":"Else","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.bulcan.2024.12.004_bib0380","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/bjh.14129","article-title":"Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial","volume":"174","author":"Chihara","year":"2016","journal-title":"Br J Haematol"},{"issue":"14","key":"10.1016\/j.bulcan.2024.12.004_bib0385","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1200\/JCO.19.02250","article-title":"Randomized Phase II study of first-line cladribine with concurrent or delayed rituximab in patients with hairy cell leukemia","volume":"38","author":"Chihara","year":"2020","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.bulcan.2024.12.004_bib0390","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.clml.2021.04.001","article-title":"First-line treatment of hairy cell leukemia with cladribine followed by rituximab consolidation significantly improves leukemia-free survival","volume":"21","author":"Amhaz","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"10.1016\/j.bulcan.2024.12.004_bib0395","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1080\/10428194.2024.2349700","article-title":"Long-term results of the sequential combination of cladribine and rituximab in hairy cell leukemia","volume":"65","author":"Marvin-Peek","year":"2024","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"10.1016\/j.bulcan.2024.12.004_bib0400","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300074","article-title":"Vemurafenib and obinutuzumab as frontline therapy for hairy cell leukemia","volume":"2","author":"Park","year":"2023","journal-title":"NEJM Evid"},{"issue":"18","key":"10.1016\/j.bulcan.2024.12.004_bib0405","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1056\/NEJMoa1506583","article-title":"Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia","volume":"373","author":"Tiacci","year":"2015","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.bulcan.2024.12.004_bib0410","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1182\/blood-2015-11-680074","article-title":"BRAF inhibition in hairy cell leukemia with low-dose vemurafenib","volume":"127","author":"Dietrich","year":"2016","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.bulcan.2024.12.004_bib0415","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1038\/s41375-021-01210-8","article-title":"Safety and efficacy of the BRAF inhibitor dabrafenib in relapsed or refractory hairy cell leukemia: a pilot phase-2\u00a0clinical trial","volume":"35","author":"Tiacci","year":"2021","journal-title":"Leukemia"},{"issue":"19","key":"10.1016\/j.bulcan.2024.12.004_bib0420","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1056\/NEJMoa2031298","article-title":"Vemurafenib plus rituximab in refractory or relapsed hairy-cell leukemia","volume":"384","author":"Tiacci","year":"2021","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.bulcan.2024.12.004_bib0425","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1182\/blood.2021013658","article-title":"Dabrafenib plus trametinib in patients with relapsed\/refractory BRAF V600E mutation-positive hairy cell leukemia","volume":"141","author":"Kreitman","year":"2023","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.bulcan.2024.12.004_bib0430","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1182\/blood.2020009688","article-title":"Phase 2\u00a0study of ibrutinib in classic and variant hairy cell leukemia","volume":"137","author":"Rogers","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bulcan.2024.12.004_bib0435","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-020-01004-y","article-title":"Moxetumomab pasudotox in heavily pre-treated patients with relapsed\/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial","volume":"14","author":"Kreitman","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"10","key":"10.1016\/j.bulcan.2024.12.004_bib0440","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1056\/NEJMc2216135","article-title":"Venetoclax in relapsed or refractory hairy-cell leukemia","volume":"388","author":"Tiacci","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.bulcan.2024.12.004_bib0445","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.3324\/haematol.2022.281754","article-title":"Allogeneic hematopoietic cell transplant for hairy cell leukemia: EBMT experience","volume":"108","author":"Chihara","year":"2023","journal-title":"Haematologica"},{"issue":"23","key":"10.1016\/j.bulcan.2024.12.004_bib0450","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.1182\/bloodadvances.2021005039","article-title":"Long-term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant","volume":"5","author":"Chihara","year":"2021","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.bulcan.2024.12.004_bib0455","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1002\/ajh.25264","article-title":"Biclonal IGHV-4-34\u00a0hairy cell leukemia variant and CLL - successful treatment with ibrutinib and venetoclax","volume":"93","author":"jJain","year":"2018","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.bulcan.2024.12.004_bib0230","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1080\/10428194.2017.1365853","article-title":"Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia","volume":"59","author":"Andritsos","year":"2018","journal-title":"Leuk Lymphoma"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455124004685?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455124004685?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T21:14:05Z","timestamp":1741122845000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455124004685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0007455124004685"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2024.12.004","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Actualit\u00e9s sur la leuc\u00e9mie \u00e0 tricholeucocytes","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2024.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}